Insulet Co. (NASDAQ:PODD) Receives $318.41 Consensus Target Price from Analysts

Insulet Co. (NASDAQ:PODD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $318.41.

Several research analysts have commented on the company. Stifel Nicolaus lifted their price target on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Raymond James reissued an "outperform" rating and issued a $360.00 price target (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research note on Tuesday, May 13th. Piper Sandler lifted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research note on Friday, May 16th.

Insulet Price Performance

PODD stock traded up $1.27 on Thursday, hitting $304.89. 316,601 shares of the company's stock traded hands, compared to its average volume of 793,016. The stock has a market cap of $21.46 billion, a price-to-earnings ratio of 52.75, a P/E/G ratio of 3.62 and a beta of 1.37. Insulet has a 1-year low of $173.00 and a 1-year high of $329.33. The stock has a fifty day moving average of $286.00 and a 200-day moving average of $274.69. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the business posted $0.73 EPS. On average, analysts forecast that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently modified their holdings of PODD. Vanguard Group Inc. grew its holdings in Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the period. Baillie Gifford & Co. raised its position in shares of Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after purchasing an additional 79,982 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Insulet by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock worth $463,347,000 after purchasing an additional 40,566 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after buying an additional 297,734 shares in the last quarter. Finally, Groupama Asset Managment increased its position in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock worth $276,728,000 after acquiring an additional 3,759 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.